Free
E-newsletter
Subscribe to Housecall
Our weekly general interest
e-newsletter keeps you up to date
on a wide variety of health topics.
close window
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Risk factors
By Mayo Clinic staffWegener's granulomatosis can begin at any age, but it most often starts in middle age, with an average onset between 40 and 65. Whites are more likely than blacks to develop Wegener's granulomatosis.
References
- Longo DL, et al. Harrison's Online. 18th ed. New York, N.Y.: The McGraw-Hill Companies; 2012. http://www.accessmedicine.com/resourceTOC.aspx?resourceID=4. Accessed Oct. 12, 2012.
- Granulomatosis with polyangiitis (Wegener's). American College of Rheumatology. http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/wegeners.asp. Accessed Oct. 12, 2012.
- Holle JU, et al. Clinical manifestations and treatment of Wegener's granulomatosis. Rheumatologic Disease Clinics of North America. 2010;36:507.
- Papadakis MA, et al. Current Medical Diagnosis & Treatment 2013. 52nd ed. New York, N.Y.: The McGraw-Hill Companies; 2013. http://www.accessmedicine.com/resourceTOC.aspx?resourceID=1. Accessed Oct. 12, 2012.
- Falk RJ, et al. Clinical manifestations and diagnosis of Wegener's granulomatosis and microscopic polyangiitis. http://www.uptodate.com/index. Accessed Sept. 21, 2012.
- FDA approves Rituxan to treat two rare disorders. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251946.htm. Accessed Aug. 22, 2012.
- Langford CA. Update on the treatment of granulomatosis with polyangiitis (Wegener's). Current Treatment Options in Cardiovascular Medicine. 2012;14:164.
- Turnball J, et al. Adverse effects of therapy for ANCA-associated vasculitis. Best Practice and Research Clinical Rheumatology. 2009;23:391.
Find Mayo Clinic on